Jaguar Health Completes Bridge Financing

Jaguar Health, Inc. has announced the closure of its previously declared private placement. This financing resulted in approximately $3.448 million through convertible promissory notes issued to institutional and accredited investors. These notes, with a 6% annual interest rate and three-month maturity, are convertible into company stock.

Additionally, Jaguar Health issued warrants to investors, potentially exercisable for five years. The financing aims to support Jaguar's development of crofelemer for rare diseases and therapy-related diarrhea, with key developments anticipated in Q2 2025.

The gross proceeds will support the company's working capital and corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for this transaction.